© 2020 MJH Life Sciences and HCPLive. All rights reserved.
July 28, 2020
Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.
July 27, 2020
A new analysis of a trio of intravitreal agents show maintained visual acuity in treatment-naive patients for at least 5 years.
The specialty is on the precipice of advancement. What gets it over the hurdle?
A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.
July 26, 2020
A look at how the specialty functions in telemedicine, and how it could work better with primary care physicians and endocrinologists.
How the condition affects both the vision and mindset of patients, and what clinical outcomes for anti-VEGF research do to address it.
July 25, 2020
A look at how primary care patients begin to present with diabetic retinopathy risk.
July 24, 2020
As of February, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.
July 20, 2020
Cataracts and diabetic retinopathy are the 2 leading causes of acquired blindness worldwide.
July 11, 2020
It is important to understand how and why disease risk and health burden vary by socioeconomic status.